like
vaccin
biolog
protein
immunogen
reason
includ
rout
administr
dose
frequenc
underli
antigen
therapeut
protein
impact
immunogen
quit
sever
regulatori
agenc
develop
riskbas
guidelin
immunogen
screen
cell
epitop
root
immunogen
issu
present
cell
activ
process
antidrug
antibodi
develop
preclin
screen
cell
epitop
perform
silico
follow
vitro
vivo
valid
importantli
screen
immunogen
complic
discoveri
regulatori
cell
epitop
suggest
immunogen
test
must
take
regulatori
cell
consider
review
address
applic
comput
tool
preclin
immunogen
assess
implic
discoveri
regulatori
cell
epitop
experiment
valid
assess
biotechnolog
revolut
made
great
stride
recent
year
drug
develop
produc
novel
therapeut
protein
includ
monoclon
antibodi
mab
antibodylik
protein
scaffold
howev
push
deliv
novel
biolog
market
develop
occas
overlook
factor
may
contribut
protein
immunogen
sometim
disastr
result
depend
therapeut
context
autolog
humanlik
protein
proven
surprisingli
immunogen
suggest
assumpt
immun
toler
also
requir
care
consider
biolog
design
fortun
year
thorough
studi
paramet
influenc
vaccin
immunogen
efficaci
allow
parallel
drawn
protein
therapeut
factor
deliveri
rout
vehicl
formul
dose
innat
immun
system
activ
abil
protein
interfac
humor
b
cell
cellular
cell
immun
system
may
influenc
potenti
immunogen
protein
degre
whether
protein
administ
therapeut
purpos
enzym
monoclon
replac
protein
vaccin
cellular
humor
immun
respons
may
result
therapeut
protein
administr
similar
effect
vaccin
antidrug
antibodi
ada
may
neutral
therapeut
effect
drug
andor
alter
pharmacokinet
cell
certainli
involv
immun
respons
igg
class
ada
observ
antibodi
isotyp
switch
key
function
tdepend
antigen
seriou
advers
event
provok
ada
crossreact
critic
autolog
protein
two
exampl
undesir
ada
respons
includ
autoimmun
thrombocytopenia
itp
follow
exposur
recombin
thrombopoietin
pure
red
cell
aplasia
associ
particular
formul
erythropoietin
eprex
sinc
effect
immunogen
quit
sever
regulatori
agenc
develop
riskbas
guidelin
immunogen
screen
cell
epitop
content
one
factor
contribut
antigen
bind
strength
cell
epitop
major
histocompat
complex
mhc
hla
molecul
key
determin
cell
epitop
immunogen
allow
epitop
higher
bind
affin
like
display
surfac
cell
context
mhc
molecul
recogn
correspond
cell
receptor
tcr
thu
fate
protein
drug
may
determin
constitu
correspond
hla
bind
affin
fortun
year
develop
valid
cell
epitop
predict
rel
accur
use
silico
tool
result
immunoinformat
tool
appli
triag
protein
therapeut
higher
risk
lower
risk
categori
prior
clinic
develop
base
cell
epitop
content
therefor
find
peptid
sequenc
may
trigger
altern
suppress
cell
respons
may
import
step
taken
preclin
develop
protein
drug
one
approach
measur
potenti
immunogen
protein
pars
protein
sequenc
overlap
peptid
frame
search
potenti
cell
epitop
estim
hla
bind
potenti
short
sequenc
silico
eight
common
class
ii
hla
allel
cover
major
human
genet
background
critic
step
process
use
algorithm
normal
hla
allelespecif
score
order
abl
compar
score
across
multipl
hla
allel
approach
normal
across
allel
highli
like
overpredict
select
hla
therebi
skew
analysi
reduc
accuraci
potenti
immunogen
protein
repres
sum
score
overlap
peptid
frame
potenti
singl
peptid
sequenc
immunogen
estim
cumul
hla
bind
score
appli
approach
biolog
usual
autolog
protein
monoclon
foreign
protein
discov
silico
signatur
bind
score
cell
epitop
tend
within
one
two
deviat
mean
set
random
protein
sequenc
allow
rel
accur
predict
potenti
cell
epitop
howev
knowledg
potenti
hla
bind
translat
knowledg
type
cell
respons
may
ensu
potenti
effector
inflammatori
regulatori
suppress
cell
immun
may
activ
complic
process
screen
immunogen
presenc
cell
epitop
may
contribut
immunogen
suffici
control
factor
appear
context
cell
epitop
recogn
cell
signal
evok
releas
inflammatori
cytokin
result
express
costimulatori
factor
antigenpres
cell
effector
immun
respons
trigger
absenc
signal
presenc
other
abund
regulatori
cytokin
cell
may
deviat
toward
regulatori
tolerogen
respons
thu
protein
biolog
cell
epitop
may
friend
regulatori
foe
effector
depend
context
respons
fig
import
observ
turn
regulatori
cell
epitop
may
key
featur
biolog
drug
exist
role
immun
respons
biolog
yet
well
understood
immunogen
factor
foreign
cell
epitop
content
danger
signal
toler
selfprotein
integr
aspect
immun
system
without
immun
respons
would
sever
hamper
danger
self
despit
import
toler
regul
autoreact
immun
respons
quit
clear
toler
overcom
cell
epitop
contribut
induct
immun
respons
autolog
protein
mani
parallel
develop
autoimmun
diseas
immunogen
therapeut
protein
includ
reduct
regulatori
cell
treg
immun
respons
induct
effector
respons
deviat
immun
respons
away
toler
toward
immunogen
probabl
involv
b
cell
effector
cell
danger
signal
tolllik
receptor
ligand
sinc
toler
consid
normal
state
immun
respons
autolog
protein
develop
ada
recombin
autolog
protein
regard
breach
toler
autoreact
b
cell
found
normal
individu
cell
rare
stimul
produc
antibodi
circul
level
nativ
protein
presenc
low
level
circul
antibodi
autolog
protein
wellknown
phenomenon
drug
develop
autoantibodi
rare
interfer
drug
contrast
presenc
cell
respons
autolog
protein
critic
determin
autoimmun
diseas
also
contribut
develop
higher
level
antiself
antibodi
provid
cytokin
help
b
cell
immun
respons
autolog
protein
occur
theori
b
cell
receptor
self
elimin
cours
immun
matur
thymu
cell
bone
marrow
b
cell
howev
evid
autoreact
cell
present
peripher
circul
thymic
delet
selfreact
cell
imperfect
autoreact
cell
escap
peripheri
low
avid
absenc
thymic
express
ineffici
express
ineffici
process
cell
epitop
document
diabet
rheumatoid
arthriti
multipl
sclerosi
toler
self
overcom
danger
signal
present
crossreact
self
epitop
epitop
pathogen
trigger
effector
immun
respons
self
eg
human
coronaviru
lyme
diseas
antigen
import
danger
signal
develop
effector
respons
autolog
protein
worth
bear
mind
sinc
mani
protein
therapeut
produc
use
method
may
incorpor
signal
level
usual
limit
detect
anoth
factor
may
play
role
induct
autoimmun
known
heterolog
immun
cell
respons
epitop
crossreact
self
unfortun
role
heterolog
immun
develop
ada
protein
therapeut
remain
unexplor
present
even
though
like
contribut
factor
context
b
cell
respons
develop
antibodi
includ
autoantibodi
tindepend
tdepend
although
cell
independ
ti
antibodi
develop
often
note
sourc
antibodi
protein
therapeut
ti
activ
b
cell
gener
lead
antibodi
affin
matur
b
cell
memori
commonli
cell
depend
td
activ
b
cell
trigger
lead
robust
antibodi
respons
affin
matur
isotyp
switch
develop
b
cell
memori
induct
igg
class
ada
whether
chimer
antibodi
human
antibodi
recombin
protein
protein
nonhuman
origin
normal
impli
sequenc
protein
trigger
cell
respons
led
td
b
cell
respons
thu
isotyp
switch
sourc
danger
signal
may
quit
differ
vaccin
biolog
protein
vaccin
adjuv
contain
innat
immun
system
trigger
complet
freund
adjuv
cpg
oligodeoxynucleotid
adjuv
exampl
tolllik
receptor
tlr
ligand
tlr
pattern
recognit
receptor
express
antigenpres
cell
recogn
structur
conserv
molecular
pattern
microb
lp
bacteri
dna
certain
bacteri
polysaccharid
protein
therapeut
rule
highli
purifi
protein
contain
danger
signal
process
manufactur
may
lead
introduct
tlr
ligand
altern
compon
formul
may
degrad
cours
drug
process
formul
lead
format
danger
signal
see
exampl
discuss
eprex
summari
three
critic
factor
contribut
immun
respons
protein
therapeut
first
b
cell
must
recogn
protein
antigen
nativ
form
use
b
cell
receptor
membran
bound
immunoglobulin
second
b
cell
antigenpres
cell
apc
must
process
present
cell
epitop
deriv
protein
therapeut
trigger
cell
respons
third
danger
signal
requir
creat
proper
context
trigger
cell
respons
regardless
initi
trigger
immun
respons
protein
drug
whether
antibodi
recombin
human
protein
fviii
erythropoietin
myozym
due
combin
activ
b
cell
recogn
antigen
presenc
danger
signal
trigger
cell
begin
path
matur
thymu
fate
reach
peripheri
process
begin
cell
engag
epitopeload
mhc
surfac
antigenpres
cell
cell
receptor
seri
molecular
event
ensu
result
differenti
express
function
phenotyp
marker
make
possibl
experiment
distinguish
one
cell
type
anoth
stimulatori
inhibitori
respons
mediat
effector
regulatori
cell
respect
gener
effector
cell
produc
inflammatori
respons
clear
infect
wherea
regulatori
cell
gener
suppress
respons
promot
immunolog
toler
effector
cell
fall
two
broad
class
helper
cell
th
cytotox
lymphocyt
ctl
phenotyp
popul
distinguish
cell
surfac
protein
th
cell
express
ctl
th
cell
orchestr
event
critic
humor
cellular
arm
adapt
immun
system
prime
ctl
b
cell
respons
gener
secondari
respons
contribut
induct
sustain
immun
memori
helper
cell
critic
import
instig
ada
respons
cell
receptor
tcr
assur
immun
respons
specif
interact
epitopeload
mhc
antigenpres
cell
apc
tcr
pleiomorph
b
cell
receptor
immunoglobulin
case
cell
tcr
recogn
mhc
class
ii
molecul
express
dendrit
cell
macrophag
b
cell
antidrug
immun
respons
commenc
ingest
protein
drug
apc
dendrit
cell
b
cell
foreign
antigen
taken
apc
endocyt
vesicl
proteas
degrad
protein
peptid
endosom
fuse
mhc
class
iicontain
vesicl
miic
vesicl
enabl
peptid
bind
mhc
molecul
concentrationdepend
manner
aid
hladm
peptid
compet
bind
mhc
groov
peptidemhc
complex
transport
cell
surfac
present
cell
cell
tcr
bind
mhc
class
iiepitop
complex
activ
costimulatori
interact
signal
fig
tcr
activ
switch
downstream
signal
pathway
cell
lead
secret
cytokin
turn
stimul
intracellular
signal
bind
autocrin
fashion
receptor
lead
cell
prolifer
activ
th
cell
secret
wide
rang
cytokin
includ
interferongamma
hallmark
cytokin
major
th
lineag
respect
although
commit
particular
cell
subset
necessarili
fix
current
subject
intens
investig
function
classic
treg
subset
welldescrib
cell
activ
macrophag
aid
expans
ctl
cell
aid
adapt
humor
respons
trigger
b
cell
produc
antibodi
signal
fig
cell
secret
third
newest
major
th
lineag
proinflammatori
import
pathogen
defens
interestingli
cell
induc
becom
regulatori
cell
underscor
flexibl
cell
subset
cell
epitopespecif
immun
respons
exhibit
differ
phenotyp
depend
context
immun
respons
helper
cell
secret
play
import
role
develop
b
fig
cell
epitop
may
trigger
effector
immun
respons
character
inflammatori
cytokin
regul
b
cell
activ
develop
antidrug
antibodi
regulatori
cell
respons
character
suppressor
cytokin
decreas
cellular
prolifer
decreas
antibodi
secret
context
immun
respons
import
factor
determin
cell
phenotyp
memori
cell
absenc
help
b
cell
expand
affin
matur
isotyp
switch
fig
b
dysfunct
inappropri
respons
elicit
cell
give
rise
number
diseas
condit
exampl
inappropri
respons
associ
cell
give
rise
allerg
diseas
inappropri
respons
associ
cell
may
result
autoimmun
diseas
cell
respons
fundament
defin
epitop
rather
phenotyp
determin
environ
epitop
present
cell
regulatori
suppressor
cell
key
player
complex
set
interact
regul
immun
respons
ensur
toler
self
two
type
toler
central
peripher
central
cell
toler
occur
thymic
develop
cell
high
affin
tcr
autolog
epitop
delet
b
cell
recogn
selfprotein
may
similarli
delet
bone
marrow
addit
peripher
toler
mechan
exist
control
autoimmun
prevent
autoreact
lymphocyt
exit
thymu
bone
marrow
accord
current
think
autoreact
cell
moder
affin
may
escap
delet
convert
function
natur
regulatori
cell
ntreg
suppress
autoimmun
toler
peripheri
character
plastic
cell
lineag
commit
matur
cell
convert
treg
phenotyp
upon
activ
cell
receptor
presenc
role
adapt
treg
atreg
cell
may
dampen
effector
immun
respons
either
control
vigor
proinflammatori
immun
reaction
infect
possibl
facilit
coexist
benefici
symbiot
bacteria
virus
treg
exhibit
phenotyp
protein
import
stimul
helper
th
cell
antigen
involv
first
activ
interleukin
present
antigen
surfac
antigenpres
cell
usual
macrophag
dendrit
cell
b
cell
associ
class
ii
major
histocompat
complex
molecul
mhc
ii
extrins
foreign
protein
requir
initi
captur
protein
follow
denatur
andor
degrad
associ
molecul
fragment
mhc
ii
cell
stimul
way
express
receptor
interleukin
secret
variou
molecul
includ
factor
stimul
b
cell
divid
andor
secret
ig
interferongamma
turn
caus
prolifer
th
cytotoxicsuppressor
cell
encount
antigen
b
cell
result
process
present
epitop
b
cell
surfac
context
mhc
costimulatori
factor
interact
memori
b
cell
result
secret
cytokin
cell
cytokin
allow
b
cell
matur
becom
dedic
iggproduc
isotyp
switch
memori
b
cell
maintain
toler
attenu
express
associ
autoimmun
diseas
major
function
regulatori
cell
regul
cellmedi
immun
suppress
autoimmunogen
cell
destroy
develop
thymu
extrem
import
help
prevent
autoimmun
diseas
treg
promot
transform
growth
factorbeta
lead
induct
express
turn
render
cell
suppress
function
treg
secret
specif
cytokin
suppress
effect
effector
respons
cytokin
import
cell
prolifer
contribut
signal
transduct
treg
mainten
homeostasi
competit
fit
natur
treg
cell
stimul
cell
antigen
vitro
presenc
led
induct
express
howev
follow
restimul
antigen
absenc
exogen
cell
seem
lose
express
cytokin
produc
regulatori
cell
play
role
maxim
suppress
activ
immun
cell
convers
shown
play
repress
role
transcript
activ
drive
cell
fate
determin
away
treg
lineag
studi
anim
model
autoimmun
also
shown
increas
frequenc
sever
autoimmun
absenc
treg
transfer
treg
cell
suffici
protect
revers
autoimmun
also
antigenspecif
induc
regulatori
cell
express
stabli
may
gener
transplant
toler
prevent
aid
autoimmun
allergi
inflamm
b
cell
antibodi
gener
recogn
conform
epitop
surfac
protein
cell
recogn
linear
epitop
deriv
protein
process
apc
describ
antigen
autolog
protein
broken
proteolyt
enzym
apc
process
larg
number
peptid
fragment
produc
one
fragment
could
cell
epitop
fragment
gener
right
amino
acid
side
chain
allow
bind
mhc
bind
groov
present
surfac
apc
one
critic
determin
immunogen
strength
cell
epitop
bind
mhc
molecul
peptid
bind
higher
affin
mhc
like
display
cell
surfac
recogn
tcr
effector
treg
tcr
bind
mhcpeptid
complex
far
determin
natur
cell
treg
effector
determin
overal
effect
cell
respons
cell
epitop
sequenc
affin
mhc
appear
differ
cell
type
last
decad
research
develop
number
comput
algorithm
map
locat
mhc
class
iand
class
iirestrict
cell
epitop
within
protein
variou
origin
silico
method
includ
frequenc
analysi
supportvector
machin
hidden
markov
model
neural
network
recent
review
cell
epitopemap
tool
see
sett
brusic
de
groot
among
other
tool
common
abil
quickli
screen
larg
volum
protein
sequenc
put
cell
epitop
preliminari
screen
reduc
search
space
dramat
typic
least
mhc
class
ii
predict
method
use
evalu
td
immunogen
mhc
class
iirestrict
cell
provid
help
b
cell
lead
develop
ada
silico
predict
helper
epitop
alreadi
success
appli
design
vaccin
select
epitop
studi
autoimmun
author
use
epimatrix
system
valid
follow
decad
use
vitro
vivo
studi
eg
epimatrix
employ
hla
class
class
ii
pocket
profil
describ
hla
pocket
bind
coeffici
appli
coeffici
predict
overlap
peptid
epitop
framebyallel
evalu
consid
singl
assess
epimatrix
assess
score
zscore
equal
defin
hit
say
potenti
immunogen
worthi
consider
sampl
analysi
provid
fig
epimatrix
report
provid
fig
illustr
import
concept
cell
epitopesthos
immunogen
tend
one
mhc
hla
bind
motif
anoth
way
say
best
cell
epitop
tend
contain
cluster
hla
bind
motif
cluster
highli
correl
immunogen
found
cell
epitop
cluster
rang
roughli
amino
acid
length
consid
affin
multipl
allel
across
multipl
frame
contain
anywher
bind
motif
cluster
score
calcul
sum
epimatrix
score
eight
class
ii
allel
cluster
score
higher
consid
signific
notic
mani
reactiv
cell
epitop
cluster
concentr
singl
frame
featur
refer
epibar
shown
fig
epibar
fig
influenza
ha
peptid
epitop
known
promiscu
immunogen
high
zscore
allel
epimatrix
rank
epimatrix
score
color
shown
zscore
legend
peptid
predict
zscore
approxim
top
deriv
given
protein
signific
chanc
bind
mhc
molecul
score
approxim
top
highli
like
bind
mhc
molecul
cluster
score
calcul
sum
epimatrix
score
eight
class
ii
allel
cluster
score
higher
consid
signific
influenza
ha
peptid
shown
cluster
score
bandlik
pattern
epibar
show
hit
potenti
bind
eight
class
ii
allel
characterist
promiscu
epitop
singl
frame
predict
bind
least
four
differ
hla
allel
sequenc
contain
epibar
includ
influenza
hemagglutinin
cluster
score
tetanu
toxin
cluster
score
cluster
score
signific
promiscu
bind
underscor
associ
immunodomin
illustr
sever
protein
includ
tetanu
toxin
influenza
hemagglutinin
hepat
b
viru
nucleocapsid
antigen
hepat
c
viru
nonstructur
protein
hiv
protein
gag
nef
consid
overal
immunogen
potenti
whole
protein
epimatrix
zscore
sum
hit
adjust
length
protein
test
larg
number
randomli
gener
protein
sequenc
expect
valu
zero
determin
averag
score
random
protein
sequenc
protein
sequenc
compar
standard
fig
protein
score
top
quartil
distribut
roughli
speak
protein
score
contain
unusu
high
number
potenti
cell
epitop
method
describ
number
public
recent
de
groot
et
al
clinic
immunolog
importantli
presenc
one
domin
cell
epitop
cluster
enabl
signific
immun
respons
otherwis
lowscor
protein
therefor
evalu
immunogen
potenti
consid
overal
potenti
also
region
potenti
cell
epitopemap
tool
epimatrix
highli
accur
predictor
immun
respons
illustr
predict
capabl
epimatrix
recent
analyz
set
highli
immunogen
peptid
epitop
includ
commerci
reagent
ceft
produc
panatec
commonli
use
posit
control
immunolog
test
elispot
cytokin
flow
cytometri
shown
tabl
analyz
epitop
ceft
reagent
previous
identifi
promiscu
epitop
peptid
pool
contain
eight
hla
class
iirestrict
peptid
influenza
viru
eight
epsteinbarr
viru
six
tetanu
toxin
one
human
cytomegaloviru
tabl
ceft
reagent
immunogen
measur
releas
elispot
prolifer
cfse
assay
contain
peptid
restrict
eight
archetyp
class
ii
allel
use
epitop
predict
epimatrix
ceft
peptid
sequenc
evalu
use
epimatrix
panel
class
ii
predict
matric
base
estim
probabl
mhc
bind
result
zscore
fall
common
scale
directli
compar
across
hla
allel
tabl
nearli
wellknown
cell
epitop
cluster
immunogen
potenti
epibar
correspond
epimatrix
predict
high
seventeen
twenti
peptid
includ
ceft
reagent
correctli
predict
bind
specifi
allel
use
epimatrix
neg
predict
valu
epimatrix
npv
calcul
illustr
ceft
analysi
base
immunogen
score
peptid
sequenc
possibl
make
inform
decis
likelihood
peptid
sequenc
provok
immun
respons
shown
next
section
use
epimatrix
immunogen
scale
prospect
predict
clinic
immunogen
novel
peptibodi
bioengin
autolog
protein
silico
screen
along
ex
vivo
immunogen
test
use
evalu
protein
therapeut
preclin
develop
two
exampl
correctli
predict
clinic
immunogen
protein
therapeut
includ
fpx
gdnf
subsequ
publish
fpx
recombin
fusion
protein
consist
two
ident
biolog
activ
peptid
link
human
fc
fragment
epimatrix
predict
strong
signal
immunogen
within
acid
carboxytermin
region
peptid
portion
fpx
administr
fpx
healthi
human
subject
develop
antibodi
singl
inject
memori
cell
respons
carboxyterminu
peptid
observ
antibodi
posit
subject
antibodi
neg
subject
predict
promiscu
predict
cell
epitop
confirm
represent
common
hla
allel
antibodi
posit
subject
hlahaplotyp
predict
associ
highest
cell
antibodi
respons
confirm
cell
antibodi
assay
tatarewicz
mox
also
use
epimatrix
screen
gdnf
protein
therapeut
subsequ
proven
immunogen
clinic
trial
protein
contain
epitop
cluster
rank
high
wellknown
immunogen
epitop
epimatrix
immunogen
scale
fig
sever
public
also
link
cell
epitop
immun
respons
immunogen
exampl
barbosa
et
al
confirm
role
cell
immun
respons
betaseron
link
ada
hladr
type
addit
two
publish
studi
silico
assess
predict
clinic
immunogen
least
two
unpublish
studi
vibha
jawa
person
commun
help
cytotox
cell
respons
requir
enhanc
efficaci
vaccin
virus
import
cell
help
nowher
obviou
influenza
vaccin
convent
influenza
vaccin
design
stimul
protect
antibodi
respons
hemagglutinin
ha
even
though
cell
help
requir
fig
summari
immunogen
scale
find
select
autolog
protein
show
antibodi
sequenc
rank
compar
standard
control
epimatrix
protein
immunogen
score
higher
consid
potenti
immunogen
note
lowscor
protein
lower
left
side
scale
known
engend
littl
immunogen
higher
score
protein
upper
left
side
scale
known
immunogen
monoclon
antibodi
adjust
antibodi
score
presenc
predefin
regulatori
cell
epitop
evid
presenc
epitop
decreas
overal
immunogen
antibodi
clinic
discov
peptid
sequenc
identifi
put
cell
epitop
may
potenti
import
aspect
protein
therapeut
develop
tabl
epimatrix
analysi
ceft
peptid
pool
continu
next
page
high
specif
igg
antibodi
titer
ha
antigen
antibodi
titer
usual
rel
weak
last
long
induct
cell
respons
influenza
th
cell
epitop
improv
antibodi
respons
b
cell
epitop
gener
longterm
memori
liveattenu
influenza
vaccin
laiv
much
immunogen
suggest
betterconserv
cell
epitop
present
intern
flu
protein
present
laiv
contribut
immunogen
vaccin
therefor
presenc
cell
epitop
critic
import
induct
b
cell
respons
particularli
b
cell
memori
foreign
antigen
found
cell
epitop
contain
higher
concentr
put
mhc
bind
motif
per
amino
acid
tend
immunogen
presum
due
abil
epitop
effect
process
apc
present
rang
differ
mhc
molecul
sinc
one
bind
motif
present
therebi
trigger
rang
cell
clone
lead
synergist
effect
numer
exampl
vaccin
research
exampl
epimatrix
epitopemap
algorithm
use
identifi
highli
promiscu
cell
epitop
within
predict
secret
protein
f
tularensi
tularensi
genom
well
known
express
protein
peptid
epitop
test
elispot
assay
use
blood
human
subject
recov
f
tularensi
tularensi
infect
elispot
assay
show
posit
ifngamma
respons
individu
class
ii
peptid
peptid
pool
human
subject
although
differ
hla
restrict
molecul
contribut
subject
variabl
mhc
bind
motifrich
epitop
gener
highli
immunogen
lead
overal
posit
respons
rate
vaccin
program
inabl
specif
hla
molecul
present
epitop
given
vaccin
antigen
well
known
caus
vaccin
failur
exampl
celi
et
al
report
signific
number
hbsagreact
cell
variou
hbvimmun
individu
recogn
determin
local
near
amino
terminu
hbsag
individu
present
cell
epitop
region
unabl
mount
protect
immun
respons
follow
vaccin
exampl
lack
cell
epitop
provid
help
b
cell
led
lower
antibodi
respons
lack
help
consequ
abrog
b
cell
respons
contribut
idea
deliber
remov
cell
epitop
might
reduc
immunogen
one
first
deimmun
protein
sakstar
stapylokinas
modif
remov
specif
amino
acid
contribut
hla
bind
led
reduct
potenti
epitop
stimul
cell
respons
similarli
number
epitopeabrog
studi
perform
use
fviii
jone
et
al
identifi
sequenc
human
fviii
bound
strongli
moder
weakli
hla
class
ii
bind
assay
modifi
sequenc
epitop
reduc
potenti
bind
hla
modifi
peptid
bind
allel
less
immunogen
vitro
use
epimatrix
screen
human
antibodi
sequenc
hla
bind
sequenc
discov
seven
epitop
cluster
conserv
human
antibodi
contain
least
one
epibar
sequenc
deriv
fc
region
framework
region
variabl
domain
epimatrix
success
identifi
region
code
cell
activ
conserv
epitop
ceft
peptid
receiv
high
score
n
indic
black
peptid
receiv
moder
score
dark
grey
peptid
score
top
score
light
grey
three
twentythre
ceft
peptid
includ
reagent
ceft
shown
hla
belong
standard
set
eight
archetyp
allel
ceft
given
score
top
specifi
allel
would
normal
interpret
signific
binder
yet
epibar
present
within
sequenc
illustr
potenti
strong
candid
promiscu
epitop
fig
figur
show
epimatrix
immunogen
scale
prospect
predict
clinic
immunogen
compar
novel
protein
sequenc
protein
known
vari
immunogen
potenti
new
protein
therapeut
gdnf
use
treatment
parkinson
diseas
amyotroph
later
sclerosi
al
epimatrix
analysi
howev
score
high
publish
highli
immunogen
peptid
influenza
hemagglutinin
tetanu
toxin
might
caus
observ
side
effect
clinic
use
therapeut
suggest
play
import
immunolog
role
typic
screen
protein
immunogen
realiz
put
binder
may
fact
toler
word
epimatrix
result
interpret
mean
antibodi
sequenc
present
cell
stimul
treg
rather
effector
cell
regulatori
cell
epitop
tregitop
coincub
target
antigen
induc
bystand
toler
could
explain
rel
lower
immunogen
human
antibodi
inde
found
immunogen
therapeut
monoclon
antibodi
correl
tregitop
content
rsquar
p
find
direct
relev
biolog
industri
fig
illustr
hypothes
mechan
tregitopemedi
immunosuppress
major
implic
concept
autolog
protein
may
also
contain
regulatori
cell
epitop
therapeut
protein
interfac
immun
system
regulatori
effector
epitop
present
cell
therefor
regulatori
cell
epitop
must
also
account
address
protein
immunogen
use
cytokin
growth
factor
monoclon
antibodi
clinic
set
often
associ
develop
antibodi
direct
therapeut
protein
therefor
diminish
immunogen
therapeut
protein
without
hinder
function
may
improv
clinic
outcom
epitop
map
evalu
potenti
immunogen
immunogen
scale
one
approach
tool
use
identifi
cluster
epitop
remov
describ
previous
reduct
cell
epitop
content
associ
reduc
immunogen
accomplish
substitut
key
amino
acid
cell
epitop
sequenc
abrog
bind
hla
therebi
attenu
epitop
potenti
trigger
cell
respons
alter
cell
epitop
longer
bind
hla
therefor
uncov
immunogen
region
specif
amino
acid
residu
involv
bind
hla
allow
protein
therapeut
develop
abrog
tdepend
antibodi
respons
reduc
immunogen
candid
drug
epitopemodif
easili
evalu
vitro
vivo
prior
releas
protein
therapeut
clinic
develop
method
reduc
immunogen
also
known
deimmun
describ
detail
although
cell
autoreact
said
delet
thymic
develop
may
escap
delet
caus
prospect
epitop
autolog
protein
trigger
cell
howev
cell
epitop
cluster
consid
potenti
immunostimulatori
discuss
cell
specif
autolog
protein
escap
thymic
delet
becom
natur
regulatori
cell
treg
appear
serv
regul
suppressor
autoreact
immun
respons
therefor
epitop
induc
treg
respons
might
use
downregul
immun
respons
context
protein
therapeut
autoimmun
diseas
treg
shown
suppress
autoantibodi
thu
may
also
play
role
suppress
ada
develop
treg
epitop
tregitop
adjust
epimatrix
score
monoclon
antibodi
predict
antitherapeut
antibodi
respons
deduct
score
tregitop
epimatrix
raw
score
experi
adjust
score
better
correl
observ
clinic
immun
respons
score
protocol
enabl
categor
antibodi
four
group
low
tregitop
high
effector
neo
epitop
content
low
tregitop
low
neo
epitop
content
high
tregitop
low
neo
epitop
high
tregitop
content
high
neo
epitop
content
tabl
antibodi
low
epitop
content
antibodi
contain
regulatori
epitop
nuvion
synagi
would
less
like
induc
cellmedi
immun
respons
antibodi
contain
high
number
effector
epitop
low
number
regulatori
epitop
rituxan
predict
appear
correl
observ
immunogen
drug
clinic
case
high
number
regulatori
epitop
silenc
immun
respons
antibodi
contain
high
number
effector
epitop
may
case
humira
tabl
address
immunogen
concern
relat
low
tregitop
content
antibodi
target
sequenc
modif
may
made
sitedirect
mutagenesi
enrich
tregitop
altern
structurefunct
consider
preclud
mutagenesi
approach
tregitop
may
engin
carboxyterminu
heavi
andor
light
chain
far
antigen
bind
region
approach
could
also
adopt
reduc
immunogen
class
protein
therapeut
mean
improv
safeti
efficaci
biolog
reduc
immunogen
includ
human
pegyl
follow
fda
approv
first
therapeut
monoclon
antibodi
mab
mani
found
elicit
antidrug
antibodi
immunecompet
patient
exampl
immunosuppress
drug
use
treat
transplant
reject
first
monoclon
antibodi
approv
human
use
elicit
antibodi
patient
surprisingli
hindsight
explan
immunogen
patient
respons
foreign
mous
sequenc
improv
next
gener
mab
constant
domain
sequenc
antibodi
light
heavi
chain
replac
human
constant
region
produc
chimer
antibodi
approach
met
mix
success
chimer
antibodi
still
rais
human
anti
fig
discov
conserv
cell
epitop
igg
engag
natur
regulatori
cell
hypothes
antibodyderiv
treg
epitop
dark
blue
epitop
top
activ
regulatori
cell
lead
suppress
effector
cell
recogn
effector
epitop
red
epitop
bottom
like
igg
hypervari
region
central
toler
exist
whether
suppress
mediat
regulatori
cytokin
alon
contactdepend
signal
yet
determin
interpret
refer
color
figur
legend
reader
refer
web
version
articl
tabl
analysi
antitherapeut
antibodi
respons
relat
neo
epitop
tregitop
content
high
tregitop
content
low
tregitop
content
low
neo
epitop
content
nuvion
synagi
high
neo
epitop
content
humira
rituxan
mous
antibodi
mous
variabl
region
improv
fulli
murin
monoclon
chimer
antibodi
shown
rais
vari
immun
respons
depend
target
indic
exampl
rituximab
chimer
antibodi
elicit
immun
respons
b
cell
chronic
lymphocyt
leukemia
patient
immunogen
sjogren
syndrom
system
lupu
erythomatosu
patient
later
monoclon
antibodi
human
graft
mous
cdr
region
onto
human
scaffold
mous
sequenc
remain
encod
antigen
specif
remark
antibodi
still
immunogen
exampl
alemtuzumab
human
monoclon
antibodi
target
human
express
mani
lymphoid
neoplasm
shown
immunogen
rheumatoid
arthriti
patient
inde
complet
human
antibodi
sequenc
also
guarante
immun
stealth
rheumatoid
arthriti
crohn
diseas
patient
receiv
humira
adalimumab
tumor
necrosi
factor
alpha
inhibitor
develop
antidrug
antibodi
immunogen
antibodi
link
presenc
five
seven
key
helper
epitop
defin
number
differ
laboratori
fiona
hard
philip
sta
matt
baker
person
commun
pegyl
conjug
polyethylen
glycol
peg
biolog
also
use
reduc
immunogen
pegyl
lead
increas
protein
solubl
hydrodynam
size
allow
therapeut
protein
evad
renal
clearanc
increas
circulatori
time
bodi
larg
size
peg
molecul
may
interfer
antibodi
bind
pegyl
use
success
minim
immunogen
therapeut
enzym
arginas
asparaginas
purin
nucleosid
phosphorylas
block
antibodi
bind
prevent
diffus
small
molecul
substrat
integr
cell
epitopemap
tool
scientif
research
save
time
promis
increas
safeti
efficaci
protein
therapeut
bioinformat
tool
vitro
vivo
confirm
silico
observ
necessari
valid
cell
epitopemap
tool
use
confid
begin
new
scientif
explor
number
therapeut
protein
develop
alreadi
incorpor
silico
ex
vivo
vivo
preclin
immunogen
screen
protocol
product
develop
strategi
map
epitop
contain
recombin
autolog
therapeut
protein
may
allow
identif
subsequ
modul
therebi
reduc
chanc
biolog
induc
cellmedi
immun
respons
cell
epitop
consid
dangerousin
case
cell
epitop
associ
regulatori
cell
respons
regulatori
cell
potenti
help
develop
maintain
toler
enhanc
use
cell
epitopemap
tool
may
improv
abil
identifi
cell
epitop
friend
treg
epitop
foe
effector
epitop
context
protein
therapeut
autoimmun
enabl
us
har
import
mediat
immun
respons
effect
differenti
tcell
epitop
friend
foe
facilit
develop
less
immunogen
therapeut
smooth
progress
toward
improv
human
health
outcom
